Ista Vitrase NDA To Committee March 17; User Fee Goal April 8
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ista Pharmaceuticals’ NDA for the vitreous hemorrhage treatment Vitrase is based on two studies that show benefit on a secondary endpoint but do not reach statistical significance for the primary endpoint.